NCT00332709 - Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

OsteoporosisPostmenopausal

Interventions

DRUG

Letrozole

2.5 mg/day for 3 years

DRUG

Zoledronic acid

4 mg every 6 months

Trial Locations (23)

Novartis Investigative Site, Cologne

Novartis Investigative Site, Deggendorf

Novartis Investigative Site, Frankfurt am Main

Novartis Investigative Site, Freiburg im Breisgau

Novartis Investigative Site, Georgsmarienhütte

Novartis Investigative Site, Göttingen

Novartis Investigative Site, Halle

Novaertis Investigative Site, Hamein

Novartis Investigative Site, Hanover

Novartis Investigative Site, Höxter

Novartis Investigative Site, Ilsede

Novartis Investigative Site, Jena

Novartis Investigative Site, Karlsruhe

Novartis Investigative Site, Leer

Novartis Investigative Site, Lübeck

Novartis Investigative Site, Mannheim

Novartis Investigative Site, Münster

Novartis Investigative Site, Rostock

Novartis Investigative Site, Salzgitter

Novartis Investigative Site, Schwenningen

Novartis Investigative Site, Stendal

Novartis Investigative Site, Völklingen

Novartis Investigative Site, Witten